NCT04547777View on ClinicalTrials.gov

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Glioma, Malignant
Interventions
DRUG

D2C7-IT

D2C7-IT intratumoral infusion

DRUG

2141-V11

2141-11 intratumoral infusion

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Darell Bigner

OTHER